Journal article
Postmenopausal Hormone Therapy and Colorectal Cancer Risk by Molecularly Defined Subtypes and Tumor Location
Julia D Labadie, Tabitha A Harrison, Barbara Banbury, Efrat L Amtay, Sonja Bernd, Hermann Brenner, Daniel D Buchanan, Peter T Campbell, Yin Cao, Andrew T Chan, Jenny Chang-Claude, Dallas English, Jane C Figueiredo, Steven J Gallinger, Graham G Giles, Marc J Gunter, Michael Hoffmeister, Li Hsu, Mark A Jenkins, Yi Lin Show all
JNCI CANCER SPECTRUM | OXFORD UNIV PRESS | Published : 2020
Abstract
Background: Postmenopausal hormone therapy (HT) is associated with a decreased colorectal cancer (CRC) risk. As CRC is a heterogeneous disease, we evaluated whether the association of HT and CRC differs across etiologically relevant, molecularly defined tumor subtypes and tumor location. Methods: We pooled data on tumor subtypes (microsatellite instability status, CpG island methylator phenotype status, BRAF and KRAS mutations, pathway: adenoma-carcinoma, alternate, serrated), tumor location (proximal colon, distal colon, rectum), and HT use among 8220 postmenopausal women (3898 CRC cases and 4322 controls) from 8 observational studies. We used multinomial logistic regression to estimate odd..
View full abstractRelated Projects (1)
Grants
Awarded by National Cancer Institute, National Institutes of Health, US Department of Health and Human Services
Awarded by National Institutes of Health/National Cancer Institute Cancer Center Support Grant
Awarded by National Cancer Institute/National Institutes of Health
Awarded by German Research Council
Awarded by German Federal Ministry of Education and Research
Awarded by National Institutes of Health
Awarded by Australian National Health and Medical Research Council
Funding Acknowledgements
Genetics and Epidemiology of Colorectal Cancer Consortium: This work was supported by the National Cancer Institute, National Institutes of Health, US Department of Health and Human Services R01 CA176272, U01 CA137088, and U01 CA164930. This research was funded in part through the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA015704.The Colon Cancer Family Registry (CCFR) was supported in part by National Cancer Institute/National Institutes of Health award number U01 CA167551 and through National Cancer Institute/National Institutes of Health U01/U24 cooperative agreements with the following CCFR sites: Ontario (OFCCR) (CA074783), Seattle (SCCFR) (CA074794 and R01 CA076366), and Australasian (ACCFR) (CA074778 and CA097735). The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the CCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US government, any cancer registry, or the CCFR.CPS-II: The American Cancer Society funds the creation, maintenance, and updating of the Cancer Prevention Study II cohort. This study was conducted with Institutional Review Board approval.DACHS: This work was supported by the German Research Council (BR 1704/6-1, BR 1704/6-3, BR 1704/6-4, CH 117/1-1, HO 5117/2-1, HE 5998/2-1, KL 2354/3-1, RO 2270/8-1, and BR 1704/17-1), the Interdisciplinary Research Program of the National Center for Tumor Diseases, Germany, and the German Federal Ministry of Education and Research (01KH0404, 01ER0814, 01ER0815, 01ER1505A, and 01ER1505B).DALS: National Institutes of Health (R01 CA48998).EPIC: The coordination of EPIC is financially supported by the European Commission (DGSANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society (Denmark), Swedish Cancer Society, Swedish Research Council, and County Councils of Skane and Vasterbotten (Sweden).MCCS: This cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian National Health and Medical Research Council grants 509348, 209057, 251553, and 504711 and by infrastructure provided by Cancer Council Victoria. Cases, and their vital status were ascertained through the Victorian Cancer Registry and the Australian Institute of Health and Welfare, including the National Death Index and the Australian Cancer Database.Harvard cohort (NHS): NHS is supported by the National Institutes of Health (R01 CA137178, P01 CA087969, UM1 CA186107, R01 CA151993, R35 CA197735, K07 CA190673, and P50 CA127003).NSHDS: Swedish Cancer Society; Cancer Research Foundation in Northern Sweden; Swedish Research Council; J C Kempe Memorial Fund; Faculty of Medicine, Umea University, Umea, Sweden; and Cutting-Edge Research Grant from the County Council of Vasterbotten, Sweden.Fred Hutchinson Cancer Research Center investigators were also supported by National Institutes of Health T32 CA094880 and National Institutes of Health K05 CA152715.